Unless otherwise stated, all terms and definitions used herein shall retain the same meaning as those defined in the previous announcements dated 25 October 2024, 5 March 2025, 28 August 2025, 27 November 2025 and 20 April 2026, and Section B9 of the quarterly results of OB Holdings for the financial period ended 31 August 2025.
The Board of Directors of OB Holdings wishes to announce that Orient Biotech had received an amended Statement of Claim from NOD. In the amended Statement of Claim, NOD included, amongst others, further claims relating to Orient Biotech's obligations concerning dairy-based nutritional products and the product pipeline provisions in the NOD Agreement.
Orient Biotech denies the additional claims made in the amended Statement of Claim and has filed and served its Further Amended Defence dated 8 May 2026. The matter is currently still progressing through the procedural steps required in the litigation, with a further directions hearing listed on 21 August 2026.
Further announcements will be made to Bursa Malaysia Securities Berhad as and when there are material developments in relation thereof.
This announcement is dated 12 May 2026.